SOUTH SAN FRANCISCO, Calif. - Assembly Biosciences (NASDAQ:ASMB) priced an underwritten offering of 3,358,602 common shares at $26.50 each. The biotech also offers pre-funded warrants for up to 415,000 shares at $26.499 per warrant.
Gross proceeds are expected to reach $100 million. While the stock has fallen 7.5% over the past week, it boasts a 95% gain over the last year. With a $421 million market cap and 121% revenue growth, the company holds a solid financial position.
Investors include Gilead Sciences, Commodore Capital, Farallon Capital Management, and others. The offering is set to close on May 26, 2026. Funds will back clinical development and corporate purposes.
Guggenheim Securities and UBS Investment Bank act as joint book-running managers.
